Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Takecab

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Boehringer Ingelheim headquarters

Boehringer says anti-IL-23 drug beats Stelara in psoriasis trial

Interleukin-23 inhibitor outperforms Johnson & Johnson's blockbuster

- PMLiVE

AbbVie drops Galapagos JAK inhibitor to focus on ABT-494

Believes ABT-494 has potential to become best-in-class therapy

- PMLiVE

Blue Latitude retains Janssen contract

Strategic marketing consultancy will continue tosupport the firm's EMEA brand teams

- PMLiVE

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients

- PMLiVE

Imbruvica filed as first-line leukaemia therapy

Study shows improved progression-free survival

- PMLiVE

AbbVie’s Humira wins ninth US approval

FDA approves multi-blockbuster for inflammatory skin disease

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

Takeda’s ixazomib moves closer to US approval

Wins priority review from the FDA

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links